3-28 | by Joanne Liu (the international president of Médecins Sans Frontières.) and Paual Farmer (The co-founder of Partners in Health, Professor of Global Health and Social Medicine at Harvard Medical School, and Chief of the Division of Global Health Equity at Brigham and Women’s Hospital.) Though TB can strike anyone, it disproportionately afflicts marginalized and vulnerable populations in places like refugee camps, slums, and prisons.
3-23 | Despite being curable, the world is losing the battle against tuberculosis (TB). The road ahead is rife with challenges, from diagnosis to treatment, for patients and treatment providers alike. In this Q&A, Dr. Francis Varaine, leader of the MSF working group on Tuberculosis, explains MSF’s priorities over the next ten years. Where are we in the fight against TB? We’re not exactly winning.
7-25 | Global attention needed to prevent and treat AIDS in antiretroviral era, with 50% of hospital admissions in MSF hospitals already on treatment and showing clinical signs of failure. An unacceptably high number of people continue to develop and die of AIDS1-related diseases across sub-Saharan Africa.
6-27 | An acute humanitarian emergency is unfolding in Doolo zone, in Ethiopia’s Somali region, as malnutrition reaches alarming levels, warns Médecins Sans Frontières/Doctors Without Borders (MSF), whose teams are working in Doolo zone, the worst affected area. “The numbers of young children with severe acute malnutrition in Doolo zone are the highest ever seen in this area by our teams in the 10 years we have worked in the region,” says Saskia van der Kam, MSF nutritional advisor. MSF teams, working alongside Ethiopian health a
Fewer than 5% of people in need are treated with new TB drugs, nearly four years after their approval
3-23 | Companies and countries must take urgent action to increase access to these life-saving treatments Only 4,800 people with drug-resistant tuberculosis (DR-TB) in 2016 were treated with two newer and much more effective medicines, even though these have now been on the market for up to four years, Médecins Sans Frontières (MSF) deplored on 23 March. Outside of a small number of clinical trials and compassionate use programmes, just 469 people received delamanid in 2016, while just over 4,300 received bedaquiline.